Zhao Qun, Li Yong, Tian Yuan, Chen Yan-Ning, Tan Bi-Bo, Zhao Xüe-Feng, Jiao Zhi-Kai, Zhang Zhi-Dong, Chang Sheng-Li
Department of Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hepatogastroenterology. 2013 May;60(123):638-40. doi: 10.5754/hge121131.
We report on a case of a 65-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with capecitabine and oxaliplatin (XELOX) regimen. He underwent esophagogastroduodenoscopy, which revealed a 6x5cm gastric ulcer. Biopsy of gastric ulcer revealed adenocarcinoma. Further workups with abdominal enhancement computed tomography (CT) staged his cancer as T4N2M0. He received 2 cycles of neoadjuvant chemotherapy with XELOX without severe toxicity. Afterwards, he underwent curative surgery consisting of total gastrectomy with extended D2 lymph node dissections and a Roux-en-Y esophagojejunostomy. On microscopic examination, no tumor cells were detected in the ulcer scar of the resected stomach and in the regional lymph nodes. The benefit of XELOX regimen as neoadjuvant chemotherapy in gastric cancer is worth further investigation.
我们报告一例65岁中国男性局部晚期胃腺癌患者，其在接受卡培他滨和奥沙利铂（XELOX）方案新辅助化疗后达到病理完全缓解。他接受了食管胃十二指肠镜检查，发现一个6×5cm的胃溃疡。胃溃疡活检显示为腺癌。进一步的腹部增强计算机断层扫描（CT）检查将其癌症分期为T4N2M0。他接受了2个周期的XELOX新辅助化疗，未出现严重毒性反应。之后，他接受了根治性手术，包括全胃切除加扩大D2淋巴结清扫和Roux-en-Y食管空肠吻合术。显微镜检查显示，在切除胃的溃疡瘢痕和区域淋巴结中未检测到肿瘤细胞。XELOX方案作为胃癌新辅助化疗的益处值得进一步研究。
